Molecular Partners AG
SIX:MOLN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Savor Ltd
NZX:SVR
|
NZ |
|
Sanhe Tongfei Refrigeration Co Ltd
SZSE:300990
|
CN |
|
Karel Elektronik Sanayi ve Ticaret AS
IST:KAREL.E
|
TR |
|
Z
|
Zanlakol Ltd
TASE:ZNKL
|
IL |
|
ACCO Brands Corp
NYSE:ACCO
|
US |
|
Kozosushi Co Ltd
TSE:9973
|
JP |
|
Andon Health Co Ltd
SZSE:002432
|
CN |
|
H
|
Hengbo Holdings Co Ltd
SZSE:301225
|
CN |
|
Y
|
Yunkang Group Ltd
HKEX:2325
|
CN |
Molecular Partners AG
Accrued Liabilities
Molecular Partners AG
Accrued Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accrued Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Molecular Partners AG
SIX:MOLN
|
Accrued Liabilities
CHf8.1m
|
CAGR 3-Years
2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
|
CRISPR Therapeutics AG
NASDAQ:CRSP
|
Accrued Liabilities
$108m
|
CAGR 3-Years
5%
|
CAGR 5-Years
11%
|
CAGR 10-Years
29%
|
|
|
Basilea Pharmaceutica AG
SIX:BSLN
|
Accrued Liabilities
CHf26.2m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
6%
|
|
|
Idorsia Ltd
SIX:IDIA
|
Accrued Liabilities
CHf95.2m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Kuros Biosciences AG
SIX:KURN
|
Accrued Liabilities
CHf27.2m
|
CAGR 3-Years
76%
|
CAGR 5-Years
59%
|
CAGR 10-Years
N/A
|
|
|
Relief Therapeutics Holding SA
SIX:RLF
|
Accrued Liabilities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Molecular Partners AG
Glance View
Molecular Partners AG engages in the development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. The company is headquartered in Schlieren, Zuerich and currently employs 163 full-time employees. The company went IPO on 2014-10-22. The firm has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.
See Also
What is Molecular Partners AG's Accrued Liabilities?
Accrued Liabilities
8.1m
CHF
Based on the financial report for Dec 31, 2025, Molecular Partners AG's Accrued Liabilities amounts to 8.1m CHF.
What is Molecular Partners AG's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 5Y
1%
Over the last year, the Accrued Liabilities growth was 4%. The average annual Accrued Liabilities growth rates for Molecular Partners AG have been 2% over the past three years , 1% over the past five years .
